J
John Firth
Researcher at University of Cambridge
Publications - 17
Citations - 1602
John Firth is an academic researcher from University of Cambridge. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 11, co-authored 16 publications receiving 1543 citations. Previous affiliations of John Firth include University College London & John Radcliffe Hospital.
Papers
More filters
Journal ArticleDOI
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
Roy Y. Calne,Peter J. Friend,S.D Moffatt,Andrew Bradley,Geoff Hale,John Firth,John Bradley,Ken R. Smith,Herman Waldmann +8 more
Journal ArticleDOI
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
Roy Y. Calne,S.D Moffatt,Peter J. Friend,Neville V. Jamieson,J. A. Bradley,Gregory A. Hale,John Firth,John Bradley,Kenneth G. C. Smith,Herman Waldmann +9 more
TL;DR: This novel therapy is of equal efficacy compared to conventional triple therapy, but allows the patient to be steroid-free and to be maintained on very-low-dose immunosuppressive monotherapy, which resulted in acceptable outcomes in this group of renal allograft recipients.
Journal ArticleDOI
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data
Greg Knoll,Madzouka B. Kokolo,Ranjeeta Mallick,Andrew H. Beck,Chieny Buenaventura,Robin Ducharme,Rashad S. Barsoum,Corrado Bernasconi,Tom Blydt-Hansen,Henrik Ekberg,Claudia Rosso Felipe,John Firth,Lorenzo Gallon,M. Gelens,Denis Glotz,Jan Gossmann,Markus Guba,Ahmed Morsy,Rebekka Salgo,Earnst H Scheuermann,Helio Tedesco-Silva,Stefan Vitko,Christopher J.E. Watson,Dean Fergusson +23 more
TL;DR: Sirolimus was associated with a reduction in the risk of malignancy and non-melanoma skin cancer in transplant recipients and the use of this drug does not seem warranted for most patients with kidney transplant.
Journal ArticleDOI
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years
Christopher J.E. Watson,J. Andrew Bradley,Peter J. Friend,John Firth,Craig J. Taylor,John Bradley,Kenneth G. C. Smith,Sathia Thiru,Neville V. Jamieson,Geoff Hale,Herman Waldmann,Roy Y. Calne +11 more
TL;DR: 5‐year results of a single center study of a alemtuzumab as induction in renal transplantation are described and a powerful lymphocyte depleting antibody is evaluated in solid organ transplantation.
Journal ArticleDOI
A Randomized Controlled Trial of Late Conversion from CNI‐Based to Sirolimus‐Based Immunosuppression Following Renal Transplantation
Christopher J.E. Watson,John Firth,Paul F. Williams,John Bradley,Nicholas R. Pritchard,Afzal N. Chaudhry,J. Smith,Christopher R. Palmer,J. Andrew Bradley +8 more
TL;DR: This data indicates that conversion to sirolimus‐based immunosuppression would affect the progression of renal impairment in patients with renal impairment following renal transplantation.